Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 2/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | USP2 | O75604 | 2/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
| ▸ | LPAR5 | Q9H1C0 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20873151 | 0.83 | KDM4E (0.36) | CYP2C19CYP1A2CYP3A4KDM4E | |
| SCHEMBL20873145 | 0.80 | ADRB2 (0.34) | CYP2C19CYP1A2CYP3A4 | |
| SCHEMBL23988528 | 0.80 | ADRB2 (0.35) | CYP2C19CYP2D6CYP1A2CYP3A4KDM4E | |
| SCHEMBL15218995 | 0.79 | KDM4E (0.41) | USP2KDM4EHTTALDH1A1 | |
| SCHEMBL20873137 | 0.79 | USP2 (0.33) | CYP2C19CYP1A2CYP3A4USP2 | |
| SCHEMBL10394490 | 0.79 | USP2 (0.57) | CYP2C19CYP1A2CYP3A4USP2HTT | |
| SCHEMBL20873139 | 0.78 | SLC22A6 (0.32) | — | |
| SCHEMBL19660807 | 0.78 | KDM4E (0.40) | USP2KDM4EHTTALDH1A1 | |
| SCHEMBL15218991 | 0.78 | KDM4E (0.40) | USP2KDM4EHTTALDH1A1 | |
| SCHEMBL15218975 | 0.77 | KDM4E (0.39) | USP2KDM4EHTTALDH1A1LPAR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210340404-A1 | SILANOL COMPOSITIONS AND METHODS OF USE | 3M INNOVATIVE PROPERTIES COMPANY | 2021-11-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210340404-A1 | SILANOL COMPOSITIONS AND METHODS OF USE | EPCAM, ITGA8, CD99 | CYP2C19 2302/4885CYP2D6 2756/4885CYP1A2 1429/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.